Compare Humana Inc (HUM) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Ferrari NV — how do they compare? Humana Inc trades at $439.56 (market cap $47.61B), while Ferrari NV trades at $390.98 (market cap $68.13B). The key difference: Ferrari NV is the larger of the two by market cap, and Ferrari NV pays the higher dividend (1.09%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Ferrari NV for 126 Days on average.
| HUM | RACE | |
|---|---|---|
Market Cap | $47.61B | $68.13B |
Volume | 1,827,332 | 480,007 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $436.54 |
52-Week Low | $163.67 | $314.63 |
Typical Hold Time | 53 Days | 126 Days |
Enterprise Value | $54.97B | $70.01B |
Dividend Yield | 0.89% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Ferrari (RACE) trades at $386.39, down 0.03% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily from 2022 to 2025, supported by robust profitability margins. Recent news highlights a share buyback program and strategic partnerships, while institutional investors show increased interest.
The outlook remains positive due to strong financial performance and analyst consensus, with a price target of $462.75 implying ~20% upside. Risks include high valuation multiples, economic sensitivity, and execution challenges in electric vehicle initiatives. The stock offers growth potential but requires monitoring of competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
